Skip to content
value.today

Sermonix Pharmaceuticals, LLC

🇺🇸 Columbus, Ohio, USAPharmaceuticalsFounded 2014
Total raised
$43 M
3 rounds on record
Latest round
$40 M
Nov 2021
First round on record
Sep 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Sermonix Pharmaceuticals, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$40 MNo. 3$10 to $50 million

Sermonix Pharmaceuticals, LLC: Raise no. 3, Nov 2021

Investors in this round

9 investors had bought by the notice of Nov 23, 2021: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,220,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony Wild · Executive Officer, Director
  • Barry Komm · Executive Officer
  • David Portman · Executive Officer, Director, Promoter
  • Elizabeth Attias · Executive Officer
  • Miriam Portman · Executive Officer, Promoter
  • Paul Plourde · Executive Officer
  • Simon Jenkins · Executive Officer
  • Elizabeth Garner · Director
  • Michael Friedman · Director
  • Richard De Schutter · Director
  • Thomas Pfisterer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LIFESCI CAPITAL (CRD 168404) · New York, New YorkSold in NY

Remarks in the notice

  • On the use of proceeds: “The Company will use the proceeds for general working capital purposes, including but not limited to employee salaries.”

Signed by David Portman, President. Source: SEC Form D, newest notice filed Nov 23, 2021. Read the notice at the SEC.

equitySEC
Jul 2016$2 MNo. 2Under $2 million

Sermonix Pharmaceuticals, LLC: Raise no. 2, Jul 2016

Investors in this round

2 investors had bought by the notice of Jul 11, 2016: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Ohio

People named in the notice

  • David Portman · Executive Officer, Director
  • Miriam Portman · Executive Officer, Director
  • Patrick Wiesel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Portman, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 11, 2016. Read the notice at the SEC.

equitySEC
Sep 2015$1 MNo. 1Under $2 million

Sermonix Pharmaceuticals, LLC: Raise no. 1, Sep 2015

Investors in this round

17 investors had bought by the notice of Oct 14, 2015: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities, other: Offering consists of promissory notes that are convertible into equity.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Ohio

People named in the notice

  • David Portman · Executive Officer, Director
  • Miriam Portman · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Miriam Portman, Chief Operating Officer. Source: SEC Form D, newest notice filed Oct 14, 2015. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sermonix Pharmaceuticals, LLC chose not to state its revenue in its newest notice of a funding round (Nov 2021).

    SEC Form D · Nov 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2021

That is all the official record says: Sermonix Pharmaceuticals, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Sermonix Pharmaceuticals, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sermonix Pharmaceuticals, LLC
NameRoleNamed in
Anthony WildExecutive officerNov 2021
Barry KommExecutive officerNov 2021
David PortmanExecutive officerNov 2021
Elizabeth AttiasExecutive officerNov 2021
Miriam PortmanExecutive officerNov 2021
Paul PlourdeExecutive officerNov 2021
Simon JenkinsExecutive officerNov 2021
Anthony WildDirectorNov 2021
David PortmanDirectorNov 2021
Elizabeth GarnerDirectorNov 2021
Michael FriedmanDirectorNov 2021
Richard De SchutterDirectorNov 2021
Thomas PfistererDirectorNov 2021
Miriam PortmanDirectorJul 2016
Patrick WieselDirectorJul 2016
David PortmanPromoterNov 2021
Miriam PortmanPromoterNov 2021